Normal Variants and Pitfalls of 18F_FDG PET/CT in Pediatric Oncology
Normal Variants and Pitfalls of 18F_FDG PET/CT Imaging in Pediatric Oncology
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Although pediatric cancer is relatively rare compared with adult cancer, it is the second most common cause of death, after injury in children and adolescents. lymphoma, Leukemia, and brain cancer, account for more than half of pediatric cancers, followed by neuroblastoma, soft-tissue sarcomas, Wilms tumors, and bone tumors .
18Fluorine-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) plays an important role, staging, restaging, response to treatment in childhood malignancies. PET-only examinations have been replaced by hybrid systems in the recent decades, where PET and CT are used together in oncology. In this imaging system, PET and CT are used together for functional data and morphological information, respectively. (2) Although 18F-FDG PET/CT is now well established as an accurate method for the staging and restaging of various cancers, it is also well recognized that many false-positive results can occur .
The normal distribution of FDG uptake in children differs from adults. Also, even though FDG is used widely in oncology, it is not tumor specific. Uptake of FDG may be seen in numerous benign conditions, including inflammation, infection, and trauma. Proper interpretation of pediatric FDG PET/CT studies requires knowledge of the normal distribution of FDG uptake in children, and an insight into the physiologic variants, benign lesions, and PET/CT related artifacts.
By understanding the potential causes of misinterpretation, we can increase the accuracy of interpretation, decrease the number of unnecessary follow-up studies and improve treatment outcome.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Amira Atef Mohamed, Resident doctor
- Phone Number: +20 1017064445
- Email: ameraatef781@gmail.com
Study Contact Backup
- Name: Waleed Ahmed Diaab, Ass.prof
- Phone Number: +201004242213
- Email: Waleed.diab@aun.edu.eg
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All Pediatric Cancer patients referred to nuclear medicine unit to do 18F-FDG PET/CT study.
All patients > or = 18 years.
Exclusion Criteria:
- Severely ill patients. Patients with glucose level < 200 mg/dl.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Detection normal variants and pitfalls of 18F-FDG PET/CT Imaging in Pediatric oncology that interfere in PET/CT study results and interpretation.
Time Frame: Baseline
|
Detection normal variants and pitfalls of 18F-FDG PET/CT Imaging in Pediatric oncology that interfere in PET/CT study results and interpretation by follow up with PET/CT or other imagining or clinically
|
Baseline
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- https://doi.org/10.3389/fnume.2022.825891
- Smith CS, Schoder H, Yeung HW. Thymic extension in the superior mediastinum in patients with thymic hyperplasia: potential cause of false-positive findings on 18F-FDG PET/CT. AJR Am J Roentgenol. 2007 Jun;188(6):1716-21. doi: 10.2214/AJR.06.0552.
- Bicakci N, Elli M. 18Fluorine-fluorodeoxyglucose PET/CT Imaging in Childhood Malignancies. Mol Imaging Radionucl Ther. 2021 Feb 9;30(1):18-27. doi: 10.4274/mirt.galenos.2020.64436.
- Vali R, Alessio A, Balza R, Borgwardt L, Bar-Sever Z, Czachowski M, Jehanno N, Kurch L, Pandit-Taskar N, Parisi M, Piccardo A, Seghers V, Shulkin BL, Zucchetta P, Lim R. SNMMI Procedure Standard/EANM Practice Guideline on Pediatric 18F-FDG PET/CT for Oncology 1.0. J Nucl Med. 2021 Jan;62(1):99-110. doi: 10.2967/jnumed.120.254110.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Pitfalls PET/CT In pediatric
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.